公开(公告)号：US20160222034A1

公开(公告)日：2016-08-04

申请号：US15007567

申请日：2016-01-27

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Xiaowen Peng ,  Xuri Gao ,  Yat Sun Or ,  Zachary Kevin Sweeney

IPC: C07D519/00 ,  A61K31/4188 ,  A61K45/06 ,  A61K31/427 ,  C07D491/107 ,  A61K31/4184

CPC classification number: C07D519/00 ,  A61K31/13 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4188 ,  A61K31/427 ,  A61K31/7056 ,  A61K38/19 ,  A61K38/212 ,  A61K38/215 ,  A61K38/217 ,  A61K45/06 ,  C07D403/14 ,  C07D405/14 ,  C07D491/107 ,  A61K2300/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Abstract translation: 本发明公开了式（I）的化合物及其药学上可接受的盐，酯或前药：其抑制含RNA病毒，特别是丙型肝炎病毒（HCV）。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US20160051625A1

公开(公告)日：2016-02-25

申请号：US14843119

申请日：2015-09-02

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Guoqiang Wang ,  Jiang Long ,  Xuri Gao

IPC: A61K38/13 ,  A61K45/06 ,  C07K7/64

CPC classification number: A61K38/13 ,  A61K31/7088 ,  A61K38/21 ,  A61K45/00 ,  A61K45/06 ,  C07K7/52 ,  C07K7/645 ,  Y02A50/463

Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

公开(公告)号：US20140341851A1

公开(公告)日：2014-11-20

申请号：US14245001

申请日：2014-04-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： YAO-LING QIU ,  Ce Wang ,  Xiaowen Peng ,  Hui Cao ,  Lu Ying ,  Xuri Gao ,  Bin Wang ,  Yat Sun Or

IPC: C07D498/10 ,  A61K31/4184 ,  C07D401/14 ,  A61K31/444 ,  C07D405/14 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/496 ,  C07F9/6506 ,  A61K31/675 ,  C07D487/08 ,  A61K31/506 ,  C07D409/14 ,  C07D413/14 ,  A61K31/422 ,  C07D491/107 ,  A61K31/517 ,  C07D417/14 ,  A61K45/06 ,  C07D403/14

CPC classification number: C07D498/10 ,  A61K31/13 ,  A61K31/4184 ,  A61K31/422 ,  A61K31/427 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/675 ,  A61K31/7056 ,  A61K38/19 ,  A61K38/21 ,  A61K45/06 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D487/08 ,  C07D491/107 ,  C07F9/65583 ,  A61K2300/00 ,  A61K39/12

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US12145942B2

公开(公告)日：2024-11-19

申请号：US18130641

申请日：2023-04-04

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Jiajun Zhang ,  Xuechao Xing ,  Matthew C. Rhodes ,  Xuri Gao ,  Wei Li ,  Yat Sun Or

IPC: C07D487/10

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit picornavirus, norovirus or coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a virus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230241012A1

公开(公告)日：2023-08-03

申请号：US18101258

申请日：2023-01-25

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Jorden Kass ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Byung-Chul Suh ,  Yat Sun Or

IPC: A61K31/167 ,  A61K31/4164 ,  A61K31/34 ,  A61K31/357 ,  A61K31/4409 ,  A61K31/426 ,  A61K31/4015 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4192 ,  A61K31/351 ,  A61K31/397 ,  A61K31/337 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20 ,  A61K31/401 ,  C07C303/00 ,  C07C317/44

CPC classification number: A61K31/167 ,  A61K31/4164 ,  A61K31/34 ,  A61K31/357 ,  A61K31/4409 ,  A61K31/426 ,  A61K31/4015 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4192 ,  A61K31/351 ,  A61K31/397 ,  A61K31/337 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20 ,  A61K31/401 ,  C07C303/00 ,  C07C317/44 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:


X-A-Y-L-R  (I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11384090B2

公开(公告)日：2022-07-12

申请号：US17479244

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Yong He ,  Xuri Gao ,  Jun Ma ,  Xuechao Xing ,  Hui Cao ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210230176A1

公开(公告)日：2021-07-29

申请号：US17143326

申请日：2021-01-07

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Jorden Kass ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07D493/08 ,  C07C317/44 ,  C07C323/62 ,  A61K31/167 ,  A61K31/18 ,  A61K31/196 ,  A61K31/215 ,  A61K31/223 ,  A61K31/277 ,  A61K31/325 ,  A61K31/335 ,  A61K31/336 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/39 ,  A61K31/401 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/426 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  C07B59/00 ,  C07C235/56 ,  C07C311/53 ,  C07C317/32 ,  C07C323/42 ,  C07D207/16 ,  C07D211/54 ,  C07D213/52 ,  C07D213/81 ,  C07D213/89 ,  C07D231/12 ,  C07D233/64 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D261/20 ,  C07D263/52 ,  C07D277/26 ,  C07D295/088 ,  C07D303/26 ,  C07D303/34 ,  C07D307/32 ,  C07D307/33 ,  C07D309/08 ,  C07D313/04 ,  C07D317/72 ,  C07D327/10 ,  C07D401/04 ,  C07D451/04 ,  C07D493/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10952978B2

公开(公告)日：2021-03-23

申请号：US16114842

申请日：2018-08-28

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Jorden Kass ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Byung-Chul Suh ,  Yat Sun Or

IPC: A61K31/167 ,  A61K31/4164 ,  A61K31/34 ,  A61K31/357 ,  A61K31/4409 ,  A61K31/426 ,  A61K31/4015 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4192 ,  A61K31/351 ,  A61K31/397 ,  A61K31/337 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20 ,  A61K31/401 ,  C07C303/00 ,  C07C317/44 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20200317678A1

公开(公告)日：2020-10-08

申请号：US16834259

申请日：2020-03-30

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Xiaowen Peng ,  Wei Li ,  Jorden Kass ,  Xuri Gao ,  Meizhong Jin ,  Yat Sun Or

IPC: C07D487/04 ,  A61P31/20 ,  A61K31/519

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10729688B2

公开(公告)日：2020-08-04

申请号：US16365742

申请日：2019-03-27

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Jorden Kass ,  Byung-Chul Suh ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Xuri Gao ,  Yat Sun Or

IPC: A61K31/4985 ,  C07D487/04 ,  A61K31/7105 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.